08 May 2024
ALOPECIA IS MORE COMMON THAN OBESITY
50% OF WOMEN AND MEN MAY BE AFFECTED BY ALOPECIA
Androgenetic alopecia is responsible for most hair loss cases—as many as 95%. Hair loss affects 1 in 2.5 people;[1] by comparison, obesity affects 1 in 8 people.[2] According to a CRO IQVIA 2024 report (data on file), more than 200 million patients in 15 European countries[3] are affected by androgenetic alopecia, with only 85 million receiving treatment. The value of the global alopecia market could reach €16 billion by 2028, according to the CRO IQVIA report, achieving a compound annual growth rate of 10–12%.
BioResearch Pharma S.A. (BRP), a company developing novel topical dermatological therapies based on repurposing, is developing a discovery (BRP-011) with patent protection covering 15 countries in the European Union and the United Kingdom. BRP-011 has the potential to become a new standard in the treatment of alopecia and improve the quality of life for millions of patients. The company is also working on a topical drug candidate for psoriasis (BRP-007), a problem affecting about 2% of the population.
Androgenetic alopecia is a growing civilizational problem, affecting nearly 70% of men and up to 40% of women.[4] The disease leads to a reduced quality of life for patients suffering from it and can result in depression due to low self-esteem, among other things. According to the company’s market analysis, no new drug for androgenetic alopecia has been approved for more than 25 years.
According to the World Health Organization (WHO), the number of people aged 60+ will increase from about 1.0 billion in 2020 to about 1.4 billion in 2030,[5] meaning a growing population of people facing androgenetic alopecia who will be looking for effective and readily available therapies.
“The BRP-011 product we are developing is a drug candidate for topical use in androgenetic alopecia for men and women,” explained Łukasz Zybaczyński, CEO of BioResearch Pharma S.A. “According to available analyses and reports, including the CRO IQVIA report developed for BRP, there are more than 200 million people with androgenetic alopecia in our patent area. The second project we are working on is BRP-007, a drug candidate for topical application in psoriasis with a novel mechanism of action. BRP’s projects address unmet medical needs in dermatology and, crucially, aim to improve patients’ quality of life while catering to the demand of the aesthetic medicine market, which has been stimulated by recently discovered obesity drugs. Our discoveries may also find additional relevant indications in the future, which positively affects the size of the market we can address.”
[1] https://www.ncbi.nlm.nih.gov/books/NBK430924/
[2] WHO, https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
[3] Austria, Belgium, Denmark, France, Germany, Ireland, Italy, Latvia, Lithuania, Netherlands, Poland, Spain, Sweden, Switzerland, United Kingdom
[4] CRO IQVIA report 2024, data on file
Other news
Contact us